Hydrocodone Polistirex

CHEMBL1201470 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
299.4 g/mol
LogP
2.2
Phase
4

A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.

Moleküler Ağırlık

299,4000 g/mol

LogP

2,20

TPSA

38,80 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4

InChI

InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1

Molecular Formula

C18H21NO3

HBD / HBA

- / 4

Döndürülebilir Bağlar

1

Ağır Atomlar

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Hydrocodone Polistirex is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201470. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284569. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.